评论/小综述（mini review）

FLAURA研究



Tsukita Y, Inoue A. First-line therapy in non-small cell lung cancer patients with EGFR activating mutations: a consideration of the clinical position of osimertinib based on the subset of Japanese patients in the FLAURA study. Jpn J Clin Oncol. 2022 Apr 22:hyac012. doi: 10.1093/jjco/hyac012. Epub ahead of print. PMID: 35446957.

First-line therapy in non-small cell lung cancer patients with EGFR activating mutations: a consideration of the clinical position of osimertinib based on the subset of Japanese patients in the FLAURA study - PubMed
First-line therapy in non-small cell lung cancer patients with EGFR activating mutations: a consideration of the clinical position of osimertinib based on the subset of Japanese patients in the FLAURA study | Japanese Journal of Clinical Oncology | Oxford Academic

表格多，对比了多个临床试验，是比较好的评论论文的类型。

微信扫二维码转发分享